<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560283</url>
  </required_header>
  <id_info>
    <org_study_id>HYDEAL-D-1-2016</org_study_id>
    <nct_id>NCT04560283</nct_id>
  </id_info>
  <brief_title>HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period</brief_title>
  <acronym>HYDEAL-D</acronym>
  <official_title>Randomized Clinical Trial to Assess the Efficacy and Safety of HYDEAL-D® Application in Promoting the Restoration of Sexual Function in the Postpartum Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Policlinico San Martino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During postpartum and lactation, vaginal epithelium tends to have an impaired degree of&#xD;
      hydration and lubrication. This may lead to vaginal dryness, burning sensation dyspareunia or&#xD;
      itching, which negatively affect the sexual function of puerperal women.&#xD;
&#xD;
      This study aimed to evaluate the efficacy of HYDEAL-D® vaginal gel (HYALOGYN®, Fidia&#xD;
      Farmaceutici, Abano Terme, Italy) application on promoting the restoration of sexual function&#xD;
      in the postpartum period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of sexual function by FSFI</measure>
    <time_frame>At baseline; 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Vagina; Anomaly</condition>
  <condition>Puerperium; Disease</condition>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Experimental group receiving HYALOGYN®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group undergoing expectant management</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal gel HYALOGYN®</intervention_name>
    <description>Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks</description>
    <arm_group_label>Experimental group receiving HYALOGYN®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Expectant management</intervention_name>
    <description>Expectant management for 12 consecutive weeks</description>
    <arm_group_label>Control group undergoing expectant management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women from 18 to 40 years old;&#xD;
&#xD;
          -  Women in the puerperium period (after vaginal delivery or cesarean section);&#xD;
&#xD;
          -  Women that are breast-feeding, that are not breast-feeding or that are breast-feeding&#xD;
             partially;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to hyaluronic acid gel;&#xD;
&#xD;
          -  Women non-Italian speaking;&#xD;
&#xD;
          -  Women with signs of vaginal infection;&#xD;
&#xD;
          -  Women with a history of cancer of any site with recent genital bleeding of unknown&#xD;
             origin; and patients with acute hepatopathy, embolic disorders, severe primary disease&#xD;
             of kidney;&#xD;
&#xD;
          -  Women who are attending or have attended other clinical trials within previous two&#xD;
             weeks;&#xD;
&#xD;
          -  Women with mental disorder and no insight&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Policlinico San Martino</investigator_affiliation>
    <investigator_full_name>Fabio Barra</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Puerperium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerperal Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

